A.N.M. Wymenga

1.6k total citations
41 papers, 1.1k citations indexed

About

A.N.M. Wymenga is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, A.N.M. Wymenga has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in A.N.M. Wymenga's work include Frailty in Older Adults (6 papers), Neuroendocrine Tumor Research Advances (6 papers) and Cancer survivorship and care (6 papers). A.N.M. Wymenga is often cited by papers focused on Frailty in Older Adults (6 papers), Neuroendocrine Tumor Research Advances (6 papers) and Cancer survivorship and care (6 papers). A.N.M. Wymenga collaborates with scholars based in Netherlands, Germany and United States. A.N.M. Wymenga's co-authors include Elisabeth G.E. de Vries, M.L.G. Janssen‐Heijnen, Huub Maas, Marcel G. M. Olde Rikkert, Pax H.B. Willemse, Ido P. Kema, Barbro Eriksson, J.W.R. Nortier, M. B. Jacobsen and Kjell E. Öberg and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

A.N.M. Wymenga

39 papers receiving 1.1k citations

Peers

Countries citing papers authored by A.N.M. Wymenga

Since Specialization

Citations

This map shows the geographic impact of A.N.M. Wymenga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.N.M. Wymenga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.N.M. Wymenga more than expected).

Fields of papers citing papers by A.N.M. Wymenga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.N.M. Wymenga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.N.M. Wymenga. The network helps show where A.N.M. Wymenga may publish in the future.

Co-authorship network of co-authors of A.N.M. Wymenga

This figure shows the co-authorship network connecting the top 25 collaborators of A.N.M. Wymenga. A scholar is included among the top collaborators of A.N.M. Wymenga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.N.M. Wymenga. A.N.M. Wymenga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective 2024 ·Lung Cancer ·(unknown), (unknown), (unknown), (unknown), Stefan Böhringer, Hans J.M. Smit, Pepijn Brocken, (unknown), (unknown), Pim Gal, (unknown), (unknown), (unknown), A.N.M. Wymenga, Peter G. M. Mol, J. Zwaveling, Doranne L. Hilarius	3
2	Caregivers’ burden and fatigue during and after patients’ treatment with concomitant chemoradiotherapy for locally advanced head and neck cancer: a prospective, observational pilot study 2019 ·Supportive Care in Cancer ·(unknown), Carla M.L. van Herpen, (unknown), A.N.M. Wymenga, Winette T.A. van der Graaf, Judith B. Prins	23
3	The effects of prehabilitation versus usual care to reduce postoperative complications in high-risk patients with colorectal cancer or dysplasia scheduled for elective colorectal resection: study protocol of a randomized controlled trial 2018 ·BMC Gastroenterology ·(unknown), Bart C. Bongers, (unknown), (unknown), (unknown), Frans H. de Jongh, Michiel Eijsvogel, A.N.M. Wymenga, (unknown), Job van der Palen, Marc J. van Det, N.L.U. van Meeteren, Joost M. Klaase	39
4	Willingness to accept chemotherapy and attitudes towards costs of cancer treatment; A multisite survey study in the Netherlands. 2016 ·PubMed ·(unknown), (unknown), (unknown), Job van der Palen, Winette T.A. van der Graaf, Johanna N.H. Timmer-Bonte, A.N.M. Wymenga	3
5	How did partners experience cancer patients' participation in a phase I study? An observational study after a patient's death 2015 ·Palliative & Supportive Care ·(unknown), Marlies Peters, Winette T.A. van der Graaf, A.N.M. Wymenga, Judith B. Prins, Carla M.L. van Herpen	3
6	Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer 2015 ·Investigational New Drugs ·Ruud van der Noll, Willem M. Smit, A.N.M. Wymenga, David S. Boss, Mayer B. Grob, Alwin D. R. Huitema, Hilde Rosing, Matthijs M. Tibben, (unknown), (unknown), Jos H. Beijnen, Jan H.M. Schellens	8
7	Tolerance and benefits of treatment for elderly patients with limited small-cell lung cancer 2013 ·Journal of Geriatric Oncology ·M.L.G. Janssen‐Heijnen, Huub Maas, Caro C.E. Koning, (unknown), Harry J.M. Groen, A.N.M. Wymenga	18
8	Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group 2013 ·The Breast ·Marije E. Hamaker, Caroline Seynaeve, A.N.M. Wymenga, Harm van Tinteren, J.W.R. Nortier, E. Maartense, H. de Graaf, Felix E. de Jongh, J.J. Braun, Maartje Los, Jolanda Schrama, A. Elise van Leeuwen‐Stok, (unknown), Carolien H. Smorenburg	108
9	A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study 2012 ·Annals of Oncology ·A.K.L. Reyners, Linda de Munck, Frans Erdkamp, Willem M. Smit, K. Hoekman, Roy Lalisang, H. de Graaf, A.N.M. Wymenga, M. Polée, Harry Hollema, Marcel A.T.M. van Vugt, Michael Schaapveld, P.H.B. Willemse	34
10	Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin–gemcitabine or carboplatin–paclitaxel: NVALT-3 a phase III study 2011 ·Annals of Oncology ·Bonne Biesma, A.N.M. Wymenga, Andrew Vincent, Otilia Dalesio, Hans J.M. Smit, Jos A. Stigt, Egbert F. Smit, (unknown), J.W.G. van Putten, Joris P. J. Slaets, Harry J.M. Groen	79
11	Sexual Function in Patients with Metastatic Midgut Carcinoid Tumours 2008 ·Neuroendocrinology ·Anouk N.A. van der Horst‐Schrivers, (unknown), A.N.M. Wymenga, H. Marike Boezen, (unknown), Ido P. Kema, Wim G. Meijer, Wouter W. de Herder, Pax H.B. Willemse, Thera P. Links, Elisabeth G.E. de Vries	16
12	Comprehensive Geriatric assessment and its clinical impact in oncology 2007 ·European Journal of Cancer ·Huub Maas, M.L.G. Janssen‐Heijnen, Marcel G. M. Olde Rikkert, A.N.M. Wymenga	136
13	Soft tissue sarcoma: why not treated? 2005 ·Critical Reviews in Oncology/Hematology ·(unknown), Michael Schaapveld, Albert J.H. Suurmeijer, A.N.M. Wymenga, R. Otter, Harald J. Hoekstra	9
14	The value of routine follow‐up in patients treated for carcinoma of the vulva 2003 ·Cancer ·Maaike H.M. Oonk, Joanne A. de Hullu, Harry Hollema, Marian J.E. Mourits, Elisabeth Pras, A.N.M. Wymenga, Ate G.J. van der Zee	37
15	Management of Hot Flushes in Breast Cancer Patients 2002 ·Acta Oncologica ·A.N.M. Wymenga, Dirk Th. Sleijfer	7
16	Quantification of oral mucositis due to radiotherapy by determining viability and maturation of epithelial cells 2002 ·Journal of Oral Pathology and Medicine ·Monique A. Stokman, Fred K. L. Spijkervet, A.N.M. Wymenga, F.R. Burlage, Wim Timens, Jan L.N. Roodenburg, Elisabeth G.E. de Vries	18
17	Treatment of cancer in old age, shortcomings and challenges 2001 ·The Netherlands Journal of Medicine ·A.N.M. Wymenga	27
18	Lessons from an unusual case: malignancy associated hypercalcemia, pancreatitis and respiratory failure due to ARDS 1999 ·The Netherlands Journal of Medicine ·A.N.M. Wymenga	3
19	Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome 1998 ·European Journal of Cancer ·A.N.M. Wymenga, Elisabeth G.E. de Vries, (unknown), Ido P. Kema, Jan H. Kleibeuker	25
20	A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy 1996 ·Annals of Oncology ·A.N.M. Wymenga, Winette T.A. van der Graaf, J. Wils, (unknown), George Linden, (unknown), M A Nooy, C. Van Der Heul, K.M. de Bruijn, Elisabeth G.E. de Vries	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact